SAB-185 is a human polyclonal antibody therapeutic that may have the potential to treat ill patients and provide antibodies that protect populations against COVID-19. Preclinical data has shown that SAB-185 can neutralize mutated strains of viruses successfully, according to the company.

This is a randomized, double-blind, single and multiple ascending dose study of SAB-185 that involves 28 healthy participants. SAB-185 is targeted to SARS-CoV-2 and aims to work synergistically with a patient's own immune system to both neutralize the virus and activate other immune system components.

The U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense on behalf of the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency has provided direct support for phase I and phase Ib trials of SAB-185.

Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation...

Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2.

Bruker supports COVID19-NMR Consortium
Bruker is highlighting its support of a global project called COVID19-NMR that will investigate the structure, dynamics, function, and binding of SARS-CoV-2...

SAB begins seasonal flu immunotherapy clinical trial
SAB Biotherapeutics has begun a phase I clinical trial evaluating SAB-176 for the treatment of seasonal influenza.

CSL Behring begins phase II study of COVID-19 therapy
CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory...